LncRNA LINC00342 contributes to the growth and metastasis of colorectal cancer via targeting miR-19a-3p/NPEPL1

Shen, Peng; Qu, Lili; Wang, Jingjing; Ding, Quchen; Zhou, Chuanwen; Xie, Rui; Wang, Honggang; Ji, Guozhong

doi:10.21203/rs.3.rs-35112/v3

Cited by 11 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…it is well-known that abnormal and uncontrolled proliferation is a characteristic of cancer cells (19). Furthermore, invasion and migration are considered as two dominant processes for tumor metastasis, which leads to cancer-associated mortality (20). in this regard, interruption of the aforementioned processes is an effective method for resistance of cancer metastasis.…”

Section: Discussionmentioning

confidence: 99%

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Chen

Zheng²,

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

lung cancer is one of the most common types of cancer and has a high mortality rate, worldwide. The major histopathological subtype is non-small cell lung cancer (nSclc). The aim of the present study was to investigate the role of long non-coding (lnc) rna PiTPna antisense rna 1 (PiTPna-aS1) in nSclc and elucidate its potential mechanisms. The expression of PiTPna-aS1 was determined in several nSclc cell lines. Following PiTPna-aS1-silencing, cell proliferation, invasion and migration were evaluated using cell counting Kit-8, colony formation, Transwell assay and wound healing assays, respectively. The expression levels of proliferation-, migration-and epithelial-mesenchymal transition (eMT)-associated proteins were examined using immunofluorescence assay or western blot analysis. a luciferase reporter assay was conducted to verify the potential interaction between PiTPna-aS1 and microrna(mir)-32-5p. Subsequently, rescue assays were performed to investigate the effects of PiTPna-aS1 and mir-32-5p on nSclc progression. The results demonstrated that PiTPna-aS1 was highly expressed in nSclc tissues and cell lines. it was found that PiTPna-aS1 silencing inhibited the proliferation, invasion and migration of nSclc cells. Furthermore, the protein expression of e-cadherin was upregulated, while the expression levels n-cadherin and vimentin were downregulated. The luciferase reporter assay confirmed that miR-32-5p was a direct target of PITPNA-AS1. The rescue experiments suggested that a mir-32-5p inhibitor significantly reversed the inhibitory effects of PITPNA-AS1 silencing on proliferation, invasion, migration and eMT in nSclc cells. collectively, the present results demonstrated that PiTPna-aS1 silencing could suppress the progression of nSclc by targeting mir-32-5p, suggesting a promising biomarker in nSclc diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Chen

Zheng²,

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, based on univariate and multivariate Cox regression analyses, we ultimately obtained 7 m6A-related lncRNAs that were signi cantly correlated with prognosis (LINC00342, AC018752.1, RPL34-AS1, AF117829.1, AC009948.2, SNHG10, and AL133243.3) and constructed a prognosis risk model. Studies have found that long intergenic non-protein coding RNA 00342 (LINC00342) can regulate the growth, invasion and metastasis of colorectal cancer and NSCLC cells and is closely associated with the poor prognosis of patients [48][49]. The lncRNA ribosomal protein L34 antisense RNA 1 (RPL34-AS1) is localized on human chromosome 4q25 and has antitumor effects in esophageal carcinoma and papillary thyroid carcinoma.…”

Section: Discussionmentioning

confidence: 99%

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Qiu

Wang

Fan

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Patients with advanced clear cell renal cell carcinoma (ccRCC) have a poor prognosis and lack effective prognostic biomarkers. This study uses bioinformatics analysis to identify N6-methyladenosine-related lncRNAs (m6A-related lncRNAs) as new prognostic biomarkers for ccRCC.Methods: Gene expression data and related clinical information of ccRCC patients were extracted from the Cancer Genome Atlas Database. m6A-related lncRNAs were obtained by co-expression analysis. Univariate Cox regression analysis was performed on these lncRNAs to find the prognostic-related m6A-related lncRNAs, and consensus clustering analysis was performed. The prognostic signature was screened by LASSO regression and a prognostic model was constructed. The predictive performance of the prognostic model was evaluated and validated by survival analysis and ROC curve analysis, etc. In addition, we also systematically analyzed the expression of immune checkpoints and immune cell infiltration in ccRCC patients.Results: First, 27 m6A-related lncRNAs associated with prognosis were identified, which were significantly differentially expressed between tumor and normal tissues. Consensus clustering analysis indicated that cluster 2 was associated with poor prognosis, low stromal score, high expression of PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, TIGIT, and immunosuppressive cell infiltration. The signaling pathways related to tumor progression, drug resistance, and angiogenesis and biological processes related to protein methylation and phosphatidic acid metabolism are significantly enriched in cluster 2. Subsequently, LASSO regression analysis was used to construct a prognostic risk model based on 7 m6A-related lncRNAs signature, which can be used as an independent prognostic indicator. After a series of analyses, it was shown that this model had good sensitivity and specificity, can predict the prognosis of patients with different clinical stratifications and was associated with the progression of ccRCC. The expression levels of immune checkpoints were significantly increased in high-risk patients, and there was a certain correlation between the risk score and immune cell infiltration. Conclusions: In summary, we constructed and validated a risk model that can independently predict the prognosis of ccRCC patients and reflect the immune microenvironment based on m6A-related lncRNAs; the model is conducive to the screening of biomarkers of ccRCC prognosis and may have the potential to reflect the response of ccRCCs to immunotherapy.

show abstract

“…Both studies used CRC cell lines SW480 and SW620, but their conclusions contradicted each other. Moreover, miR-203a-3p has been revealed as a tumor suppressor in gastric cancer [22], nasopharyngeal carcinoma [23] and non-small-cell lung cancer [24]. It is hard to say which study is more reliable.…”

Section: Discussionmentioning

confidence: 99%

Identification of A Four-Microrna Panel in Serum As Promising Biomarker for Colorectal Carcinoma Detection

et al. 2020

View full text Add to dashboard Cite

Background: Screening for colorectal carcinoma (CRC) lacks an efficient, inexpensive and noninvasive approach. The stable presence of serum miRNA is expected to become a new diagnostic marker. Materials & methods: Based on 135 CRC patients and 135 normal controls, this study was conducted in three phases to identify suitable serum miRNA for CRC diagnosis by using quantitative reverse transcription PCR. Bioinformatic assays were used for target genes prediction and functional annotation. Results: Serum expression level of seven miRNAs were significantly different between CRC patients and the normal controls. The final diagnostic panel (area under the curve = 0.893; sensitivity = 81.25%, specificity = 73.33%) consists of miR-203a-3p, miR-145-5p, miR-375-3p and miR-200c-3p. Conclusion: The four-miRNA panel may serve as a novel, noninvasive biomarker for CRC diagnosis and screening.

show abstract

LncRNA LINC00342 contributes to the growth and metastasis of colorectal cancer via targeting miR-19a-3p/NPEPL1

Cited by 11 publications

References 18 publications

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

N6-methyladenosine-related lncRNAs as a biomarker for predicting the prognosis and immune microenvironment of clear cell renal cell carcinoma

Identification of A Four-Microrna Panel in Serum As Promising Biomarker for Colorectal Carcinoma Detection

Contact Info

Product

Resources

About